The effect of Plasmapheresis on hypoxia in patients suffering from COVID-19

INTERVENTION: Intervention 1: Intervention group: Patients in the intervention group, in addition to the standard treatment of Covid‐19, (dexamethasone at a dose of 6 mg per day and remedSivir at a dose of 200 mg on the first day and then 100 mg daily for 7 days) will undergo the intervention (plasmapheresis). Each time plasmapheresis is performed, 40 ml per kg of body weight of the patient's plasma is replaced with 5% human albumin and 0.9% normal saline, and for each patient, if the clinical symptoms do not improve, plasmapheresis will be performed up to 3 times. Intervention 2: Control group: In this group, patients received the standard treatment of Covid‐19 according to the national protocol (Hedhexamethasone 6 mg daily and Ramdesiver 200 mg on the first day and 100 mg daily for 7 days). CONDITION: Corona virus (Covid‐19). ; J12.81 Pneumonia PRIMARY OUTCOME: Arterial blood oxygen pressure in the analysis of blood gases Pao2. Timepoint: On days zero (before the intervention), days one, three, five and seven after the intervention. Method of measurement: Blood sample to measure blood gases. Percentage of blood oxygen saturation (SPO2). Timepoint: On days zero (before the intervention), days one, three, five and seven after the intervention. Method of measurement: Pulse oximeter Bitmos Gmbh made in Germany. SECONDARY OUTCOME: C‐reactive protein (CRP) Factor. Timepoint: On days zero (before the intervention), days one, three, five and seven after the intervention. Method of measurement: Blood Test Prestige 24i machine made in Japan. Duration of hospitalization of the patient. Timepoint: End of hospitalization or death of the patient. Method of measurement: By day. INCLUSION CRITERIA: Definitive diagnosis of Covid‐19 based on taking a sample from the pharyn Xand PCR laboratory confirmation Lung involvement more than 50% SPO2 levels below 80% without oxygen or below 88% with oxygen or IL above 10 or ferritin above 1500 Patients who have not responded to other Covid‐19 treatments Age over 18 years and consent to participate in the study